Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Sponsor: Fate Therapeutics
Terminated
Incorporation of LTFU into the main interventional study.
Other terminated trials from Fate Therapeutics
Other Hematological Malignancy trials with similar outcome
Listed as NCT04093622, this observational or N/A phase trial focuses on Hematological Malignancy and remains terminated or withdrawn. Sponsored by Fate Therapeutics, it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Sep 2022 — Jul 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Dec 2021 — Sep 2022 [monthly]
Recruiting
-
Apr 2021 — Dec 2021 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Sep 2020 — Nov 2020 [monthly]
Recruiting
-
Jul 2020 — Sep 2020 [monthly]
Recruiting
-
Feb 2020 — Jul 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Feb 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fate Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .